According to Gram Research analysis, GLP-1 infusion significantly lowers angiotensin II, a hormone that raises blood pressure, but not through the mechanisms scientists expected. In a 2026 study of eight healthy men, GLP-1 reduced angiotensin II without changing the proteins that normally control it, suggesting the drug works through an unknown pathway that deserves further investigation.
Researchers discovered something surprising about GLP-1, a popular diabetes and weight-loss medication. When they gave healthy men a short infusion of GLP-1, it lowered a hormone called angiotensin II that affects blood pressure and heart health. However, the drug didn’t work the way scientists expected. Instead of changing the proteins that normally control this hormone, GLP-1 appears to work through a completely different mechanism. This finding could help doctors better understand how these medications protect the heart and kidneys, potentially opening doors to new treatments for high blood pressure and heart disease.
Key Statistics
A 2026 randomized controlled trial in Physiological Reports found that acute GLP-1 infusion significantly reduced plasma angiotensin II concentrations in eight healthy men, despite no changes in angiotensinogen, ACE, or ACE2 levels.
According to research reviewed by Gram, GLP-1 infusion increased urinary sodium excretion while lowering angiotensin II, suggesting the blood pressure benefits of GLP-1 medications may work through a previously unknown mechanism independent of traditional angiotensin system proteins.
A 2026 study demonstrated that GLP-1’s cardiovascular protective effects don’t depend on changes in circulating concentrations of angiotensinogen, ACE, ACE2, or Ang-(1-7), indicating researchers must investigate alternative pathways to explain how this drug class protects heart and kidney health.
The Quick Take
- What they studied: Whether GLP-1 medication lowers a blood pressure hormone called angiotensin II, and if so, how it does this
- Who participated: Eight healthy adult men who followed a controlled diet for 4 days before receiving either GLP-1 or a placebo injection
- Key finding: GLP-1 significantly reduced angiotensin II levels, but not through the mechanisms scientists originally thought—the drug didn’t change the proteins that normally control this hormone
- What it means for you: This research helps explain why GLP-1 drugs like Ozempic and Mounjaro may protect heart and kidney health. However, this was a small study in healthy men, so more research is needed before applying these findings to patients with heart disease or high blood pressure
The Research Details
This was a carefully controlled experiment using a crossover design, meaning each participant received both GLP-1 and a placebo on different occasions. Eight healthy men ate a standardized diet for 4 days to establish a baseline. Then, researchers gave them either GLP-1 or saline (salt water) through an IV while monitoring their blood chemistry. The study measured multiple hormones and proteins involved in blood pressure control to understand exactly how GLP-1 works.
The researchers used this specific approach because GLP-1 drugs are known to lower blood pressure and protect the heart and kidneys, but nobody fully understood the mechanism. They had a hypothesis that GLP-1 might work by activating a protein called ACE2 or by reducing angiotensinogen (a precursor hormone). By measuring all these components, they could test whether their hypothesis was correct.
This type of controlled experiment is valuable because it isolates the effect of GLP-1 from other factors in daily life. However, the small sample size and focus on healthy men limits how broadly these findings apply.
Understanding how medications work is crucial for developing better treatments. If scientists know the exact mechanism, they can potentially create drugs that work even more effectively or with fewer side effects. This research reveals that GLP-1’s blood pressure benefits don’t work through the pathways researchers expected, suggesting there may be an entirely different mechanism at play that deserves investigation.
This study has several strengths: it used a randomized, placebo-controlled design (the gold standard for testing medications), participants were carefully monitored, and the researchers measured multiple related hormones to thoroughly test their hypothesis. However, the study is very small (only 8 men), included only healthy participants (not people with actual heart or kidney disease), and was acute (short-term) rather than long-term. The findings are preliminary and need confirmation in larger, more diverse populations.
What the Results Show
When GLP-1 was infused into the participants’ bloodstreams, angiotensin II levels dropped significantly. This is important because angiotensin II is a hormone that narrows blood vessels and raises blood pressure. The drop in angiotensin II occurred only during GLP-1 infusion, not during the placebo, confirming that GLP-1 caused the effect.
However, the researchers found something unexpected: the proteins and enzymes that normally control angiotensin II didn’t change. Angiotensinogen (the precursor hormone), ACE (the enzyme that creates angiotensin II), and ACE2 (a protective enzyme) all remained stable. This was surprising because scientists had predicted that GLP-1 might work by changing one of these components.
The study also confirmed previous findings that GLP-1 increases sodium excretion through the kidneys, which helps lower blood pressure. This effect occurred alongside the drop in angiotensin II, suggesting the two effects may be related but through an unknown pathway.
The researchers measured Ang-(1-7), another hormone in the angiotensin system that has protective effects on the heart and blood vessels. This hormone remained unchanged during GLP-1 infusion. Plasma renin (an enzyme that starts the angiotensin cascade) decreased similarly during both GLP-1 and placebo infusions, suggesting this wasn’t the key mechanism either.
Previous research in humans showed that GLP-1 lowers angiotensin II and increases kidney blood flow, but the mechanism was unknown. This study confirms the angiotensin II-lowering effect and rules out several previously suspected mechanisms. The findings suggest that GLP-1 may work by changing how existing enzymes function (their activity) rather than by changing their concentration in the blood—a distinction that could explain why previous studies didn’t find the answer.
This study is small (only 8 participants) and included only healthy men, so results may not apply to women, older adults, or people with heart disease or high blood pressure. The infusion was acute (3 hours), so we don’t know if these effects persist with long-term GLP-1 use. The study measured only circulating (blood) concentrations, not what happens in tissues like the heart and kidneys. Finally, the researchers note that enzyme activity could have changed without changing concentration, which their measurements wouldn’t detect.
The Bottom Line
This research supports the existing evidence that GLP-1 medications have cardiovascular benefits, but it doesn’t change current medical practice. People taking GLP-1 drugs for diabetes or weight loss can be reassured that these medications appear to have heart-protective mechanisms. However, this study doesn’t provide evidence for starting GLP-1 specifically for blood pressure control in people without diabetes. Discuss GLP-1 therapy with your doctor based on your individual health situation.
This research is most relevant to people already taking GLP-1 medications (like semaglutide/Ozempic or tirzepatide/Mounjaro) and their doctors. It’s also important for researchers studying how these drugs work. People with high blood pressure or heart disease should not use this as evidence to start GLP-1 without medical guidance, as the study was in healthy people.
The blood pressure-lowering effect of GLP-1 appears to happen quickly (within 3 hours in this study). However, the full cardiovascular benefits likely develop over weeks to months with regular use, based on other research.
Frequently Asked Questions
How does GLP-1 medication lower blood pressure?
GLP-1 reduces angiotensin II, a hormone that narrows blood vessels and raises blood pressure. However, recent research shows it doesn’t work through the expected mechanisms—it may change how existing enzymes function rather than changing their concentration in the blood.
Is GLP-1 safe for people with high blood pressure?
GLP-1 medications appear to have heart and kidney-protective effects, which is beneficial for blood pressure control. However, only take GLP-1 if prescribed by your doctor for diabetes or weight loss. Don’t start it solely for blood pressure management without medical guidance.
Can GLP-1 replace blood pressure medications?
This research doesn’t support using GLP-1 as a replacement for blood pressure drugs. While GLP-1 may help lower blood pressure, it’s approved for diabetes and weight loss. Continue taking prescribed blood pressure medications unless your doctor advises otherwise.
How quickly does GLP-1 lower blood pressure?
This study showed angiotensin II dropped within 3 hours of GLP-1 infusion. However, the full blood pressure-lowering benefits likely develop over weeks to months with regular medication use, similar to other blood pressure drugs.
Why does this research matter if it’s only in eight people?
Small studies help scientists understand how medications work at a biological level. This research reveals GLP-1 works differently than expected, pointing researchers toward new mechanisms that could lead to better heart and kidney protection strategies.
Want to Apply This Research?
- If using a GLP-1 medication, track blood pressure readings at the same time each day (morning before eating) and record them weekly. Note any changes in sodium intake or fluid retention, as GLP-1 affects how kidneys handle salt.
- Users taking GLP-1 can use the app to monitor blood pressure trends and correlate them with medication adherence. Set reminders for consistent blood pressure checks to establish a baseline and track improvements over 8-12 weeks.
- Create a dashboard showing weekly average blood pressure readings, medication adherence, and sodium intake. Compare monthly trends to identify patterns. Share this data with your healthcare provider at regular checkups to optimize treatment.
This research describes a small, short-term study in healthy men and does not establish clinical recommendations for treating high blood pressure or heart disease. GLP-1 medications should only be used as prescribed by a healthcare provider. Do not start, stop, or change GLP-1 therapy based on this research. If you have high blood pressure, heart disease, or kidney disease, consult your doctor about appropriate treatment options. This article is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.